Department of Ophthalmology, The First People's Hospital of Xuzhou, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; First School of Clinical Medicine of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Department of Ophthalmology, The First People's Hospital of Xuzhou, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Ophthalmology. 2024 Jan;131(1):48-57. doi: 10.1016/j.ophtha.2023.08.020. Epub 2023 Aug 25.
To compare the efficacy and safety of low-level red light (LRL) in controlling myopia progression at 3 different powers: 0.37 mW, 0.60 mW, and 1.20 mW.
Single-center, single-masked, randomized controlled trial.
Two hundred children aged 6-15 with myopia of -0.50 diopter (D) or more and astigmatism of -2.50 D or less were enrolled from April to May 2022. Follow-up ended in December 2022.
Participants were assigned randomly to 3 intervention groups and 1 control group (1:1:1:1). All participants wore single-vision spectacles. Moreover, the intervention group randomly received LRL at 3 different powers twice daily for 3 minutes per session, with a minimum 4-hour interval.
Changes in spherical equivalent (SE), axial length (AL), and subfoveal choroidal thickness (SFCT) were measured.
After 6 months, SE progression was significantly lower in the 0.37-mW group (0.01 D; 95% confidence interval [CI], -0.12 to 0.15), 0.60-mW group (-0.05 D; 95% CI, -0.18 to 0.07), and 1.20-mW group (0.16 D; 95% CI, 0.03 to 0.30) compared to the control group (-0.22 D; 95% CI, -0.50 to 0.30; adjusted P < 0.001 for all). AL changes in the 0.37-mW group (0.04 mm; 95% CI, -0.01 to 0.08), 0.60-mW group (0.00 mm; 95% CI, -0.05 to 0.05), and 1.20-mW group (-0.04 mm; 95% CI, -0.08 to 0.01) were significantly smaller than the control group (0.27 mm; 95% CI, 0.22 to 0.33; adjusted P < 0.001 for all). Similarly, increases in SFCT were significantly greater in the 0.37-mW group (22.63 μm; 95% CI, 12.13 to 33.34 μm), 0.60-mW group (36.17 μm; 95% CI, 24.37 to 48.25 μm), and 1.20-mW group (42.59 μm; 95% CI, 23.43 to 66.24 μm) than the control group (-5.07 μm; 95% CI, -10.32 to -0.13 μm; adjusted P < 0.001 for all). No adverse events were observed.
LRL effectively controlled myopia progression at 0.37 mW, 0.60 mW, and 1.20 mW. Further research is required.
FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
比较低水平红光（LRL）在 3 种不同功率（0.37mW、0.60mW 和 1.20mW）下控制近视进展的疗效和安全性。
单中心、单盲、随机对照试验。
2022 年 4 月至 5 月期间招募了 200 名近视-0.50 屈光度（D）或以上且散光-2.50 D 或以下的 6-15 岁儿童。随访于 2022 年 12 月结束。
参与者被随机分配到 3 个干预组和 1 个对照组（1:1:1:1）。所有参与者均佩戴单焦眼镜。此外，干预组随机接受 3 种不同功率的 LRL，每日 2 次，每次 3 分钟，间隔至少 4 小时。
球镜等效（SE）、眼轴长度（AL）和黄斑下脉络膜厚度（SFCT）的变化。
6 个月后，0.37mW 组（0.01D；95%置信区间[CI]，-0.12 至 0.15）、0.60mW 组（-0.05D；95%CI，-0.18 至 0.07）和 1.20mW 组（0.16D；95%CI，0.03 至 0.30）的 SE 进展明显低于对照组（-0.22D；95%CI，-0.50 至 0.30；所有调整后的 P 值均<0.001）。0.37mW 组（0.04mm；95%CI，-0.01 至 0.08）、0.60mW 组（0.00mm；95%CI，-0.05 至 0.05）和 1.20mW 组（-0.04mm；95%CI，-0.08 至 0.01）的 AL 变化明显小于对照组（0.27mm；95%CI，0.22 至 0.33；所有调整后的 P 值均<0.001）。同样，0.37mW 组（22.63μm；95%CI，12.13 至 33.34μm）、0.60mW 组（36.17μm；95%CI，24.37 至 48.25μm）和 1.20mW 组（42.59μm；95%CI，23.43 至 66.24μm）的 SFCT 增加明显大于对照组（-5.07μm；95%CI，-10.32 至 -0.13μm；所有调整后的 P 值均<0.001）。未观察到不良事件。
LRL 在 0.37mW、0.60mW 和 1.20mW 时可有效控制近视进展。需要进一步研究。
作者没有与本文讨论的任何材料有关的专有或商业利益。
